Search results
Results from the WOW.Com Content Network
In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. [6] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. [7]
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.
Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform (OmniCAR), enhanced CAR-T cell manufacturing & function (CellPryme) and on two small molecule drug targeted therapies (PTX-100 & PTX-200).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise ...
Depiction of adoptive cell transfer therapy with CAR-engineered T cells. The first step in the production of CAR T-cells is the isolation of T cells from human blood. CAR T-cells may be manufactured either from the patient's own blood, known as an autologous treatment, or from the blood of a healthy donor, known as an allogeneic treatment. The ...
CAR-T — or chimeric antigen receptor T cell — therapy uses a patient’s own immune cells to treat certain blood cancers, such as leukemia, multiple myeloma and lymphoma. It involves ...
The company was established in 1995 as a spin out from the University of Oxford. [3] It was the subject of an initial public offering on the Alternative Investment Market in 1996. [4] In 2018, OXBs gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences. [5]
The announcement also includes a number to call, 1-800-FDA-1088, to report suspected adverse events associated with CAR-T therapies, including T-cell malignancies, or they can be reported at fda ...